A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and Wales
After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved today, 16 July 2024, a…